Steve Bernstein
Analyst · the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this conference call. It is now my pleasure to introduce your host, Stan Sloane, President and CEO
Thank you Stan and good afternoon. For the three-months ended July 31, 2021, consolidated revenue was $13 million, which is consistent with the same period of the prior fiscal year. The components of revenue are as follows . Revenue from commercial and U.S. government satellite programs was approximately $6.7 million, which is consistent with the same period of the prior fiscal year and accounted for approximately 52% of consolidated revenue compared to 51% of the prior fiscal year. Revenues from satellite payload contracts are recognized primarily under the percentage of completion method and are recorded only in the FEI New York segment. Revenues from non-space U.S. government and DOD customers, which are recorded in both the FEI New York and FEI-Zyfer segments were $5.5 million compared to $5.3 million in the same period of the prior fiscal year and accounted for approximately 42% of consolidated revenue compared to 41% for the prior fiscal year. Other commercial and industrial revenues were $725,000 compared to $965,000 in the prior fiscal year. Intersegment revenues are eliminated in consolidation. For the three-months ended July 31, 2021, the gross margin and gross margin rate were consistent with the same period of the prior fiscal year. Gross margin was affected by variation in engineering costs associated with programs in their development, for production phase and external issues such as COVID-19 related supply chain impacts. For the three-months ended July 31, 2021 and 2020, selling and administrative expenses were approximately 34% and 25% respectively of consolidated revenue. The increase in SG&A expense was mainly due to an increase in professional fees associated with ongoing litigation and fluctuation and other expenses. The company anticipates that SG&A expenses will decrease following settlement of the litigation issue. R&D expense for the three-months ended July 31, 2021 and 2020 increased to $1.4 million from $1.2 million, an increase of $200,000 and were 10% and 9% of consolidated revenue. The company's R&D expense increase year-over-year as R&D efforts have begun on new product development. The company plans to continue to invest in R&D to keep its products at the state-of-the-art as well as work on developing new technologies. For the three-months ended July 31, 2021, the company recorded an operating loss of $1.7 million compared to $300,000 in the prior year. In addition to factors cited above, increased professional fees associated with litigation significantly contributed to the company's operating loss for the period. Other factors that contributed were the continuing effects of the COVID-19 pandemic and engineering costs cited above. Other income consisted primarily investment income derived from the company's holdings of marketable securities. Earnings on marketable securities may vary based upon fluctuating interest rates, dividend payout levels and the timing of purchases, sales, redemptions or maturity of securities. The fluctuation in other income expense was due to less interest expense and higher other income compared to the same period of the prior fiscal year. This yields a pretax loss of approximately $1.6 million compared to $300,000 for the prior year. For the three-months ending July 31, 2021, the company recorded a tax provision of $1,000 compared to $9,000 for the prior fiscal year. Consolidated net loss for the three-months ended July 31, 2021 was $1.6 million or $0.17 per share compared to $300,000 net loss or $0.03 per share in the previous fiscal year. Our fully funded backlog at the end of July 2021 was approximately $37 million, down approximately $3 million from the previous fiscal year ended April 30, 2021. The company's balance sheet continues to reflect the strong working capital position of approximately $40 million at July 31, 2021 and a current ratio of approximately 3.6 to 1. Additionally, the company is debt-free. The company believes that it's liquidity is adequate to meet its operating and investing needs for the next 12 months and foreseeable future. Now for an explanation of the accounting associated with the legal settlement that was announced on August 25 via the company's 8-K filing. When you look at the balance sheet, you will see a current asset for $6 million called cash surrender value of life insurance current and a current liability a $5.3 million called deferred compensation current. The company surrendered life insurance policies and used available cash from deferred compensation plan assets which were previously classified as non-current assets to cover the $6 million mentioned above. The $5.3 million deferred compensation current is a liability previously accrued and was moved from long term liability to current liability as a result of the settlement. The difference between these two amounts of approximately $646,000 was recorded as an increase to accrued liabilities current and a corresponding charged to deferred compensation expense in the P&L. The effect of this settlement will be to reduce deferred compensation asset by $6 million, reduce deferred compensation liability by $5.3 million and increase deferred compensation expense in the P&L by $646,000. There is no effect on the company's cash, cash equivalents and marketable securities as a result of this settlement I will turn the call back to Stan and we look forward to your questions soon.